Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfanilamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.61 |
| ▸ | CA1 | P00915 | 14/20 | 0.61 |
| ▸ | CA12 | O43570 | 12/20 | 0.61 |
| ▸ | CA9 | Q16790 | 9/20 | 0.61 |
| ▸ | CA7 | P43166 | 8/20 | 0.61 |
| ▸ | CA4 | P22748 | 7/20 | 0.61 |
| ▸ | CA5A | P35218 | 7/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.61 |
| ▸ | CA6 | P23280 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CA3 | P07451 | 1/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.61 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfanilamide SCHEMBL30033445 | 1.00 | CA2 (0.61) | CA2CA1CA12CA9CA7 | |
| Coumarin SCHEMBL28826370 | 0.84 | CA9 (0.80) | CA2CA1CA12CA9CA7 | |
| Coumarin SCHEMBL711764 | 0.80 | CA12 (0.74) | CA2CA1CA12CA9CA7 | |
| Coumarin SCHEMBL29595600 | 0.80 | CA12 (0.95) | CA2CA1CA12CA9CA7 | |
| Coumarin SCHEMBL29827227 | 0.80 | CA12 (0.95) | CA2CA1CA12CA9CA7 | |
| Coumarin SCHEMBL7106473 | 0.78 | CA12 (0.91) | CA2CA1CA12CA9CA7 | |
| Sulfanilamide SCHEMBL27483941 | 0.78 | CA2 (0.77) | CA2CA1CA12CA9CA7 | |
| Coumarin SCHEMBL1038138 | 0.78 | CA12 (1.00) | CA2CA1CA12CA9CA7 | |
| Coumarin SCHEMBL3441294 | 0.78 | CA12 (1.00) | CA2CA1CA12CA9CA7 | |
| Coumarin SCHEMBL621751 | 0.78 | CA12 (1.00) | CA2CA1CA12CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103450132-A | Synthesis and preparation method of novel sulfanilamide-coumarin derivatives | NANJING UNIVERSITY OF TECHNOLOGY | 2013-12-18 | — | — | CN | disclosed |
| CN-103450132-A | Synthesis and preparation method of novel sulfanilamide-coumarin derivatives | NANJING UNIVERSITY OF TECHNOLOGY | 2013-12-18 | — | — | CN | disclosed |
| EP-1651958-B1 | NOVEL CHEMILUMINESCENT COMPOUNDS AND THEIR USE | ROCHE DIAGNOSTICS GMBH (DE) | 2010-06-16 | — | — | EP | disclosed |
| US-7563902-B2 | Chemiluminescent compounds and their use | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060172358-A1 | Novel chemiluminescent compounds and their use | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2006-08-03 | — | — | US | disclosed |
| EP-1651958-A1 | NOVEL CHEMILUMINESCENT COMPOUNDS AND THEIR USE | Roche Diagnostics GmbH (DE) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005015215-A1 | NOVEL CHEMILUMINESCENT COMPOUNDS AND THEIR USE | ROCHE DIAGNOSTICS GMBH (DE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172358-A1 | Novel chemiluminescent compounds and their use | LANCL1, LPO, HLCS | CA2 3061/4885CA1 1660/4885CA12 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.